ROYALTY PHARMA PLC's ticker is RPRX and the CUSIP is G7709Q104. A total of 280 filers reported holding ROYALTY PHARMA PLC in Q1 2022. The put-call ratio across all filers is 0.10 and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $836,034 | -11.5% | 31,704 | +1.9% | 0.01% | -10.0% |
| Q1 2024 | $944,446 | +148.8% | 31,098 | +130.1% | 0.01% | +100.0% |
| Q4 2023 | $379,636 | -23.2% | 13,515 | -25.8% | 0.01% | -28.6% |
| Q3 2023 | $494,437 | +22.5% | 18,218 | +38.8% | 0.01% | +40.0% |
| Q2 2023 | $403,555 | -14.8% | 13,128 | -0.1% | 0.01% | -28.6% |
| Q1 2023 | $473,542 | -8.4% | 13,143 | +0.5% | 0.01% | -12.5% |
| Q4 2022 | $516,922 | +80.7% | 13,080 | +84.0% | 0.01% | +60.0% |
| Q3 2022 | $286,000 | -2.1% | 7,108 | +2.2% | 0.01% | -16.7% |
| Q2 2022 | $292,000 | -68.0% | 6,955 | -70.3% | 0.01% | -60.0% |
| Q1 2022 | $912,000 | -1.3% | 23,397 | +1.0% | 0.02% | +7.1% |
| Q4 2021 | $924,000 | +12.1% | 23,175 | +1.7% | 0.01% | -12.5% |
| Q3 2021 | $824,000 | -16.9% | 22,794 | -5.7% | 0.02% | -11.1% |
| Q2 2021 | $991,000 | +58.1% | 24,172 | +68.1% | 0.02% | +38.5% |
| Q1 2021 | $627,000 | +164.6% | 14,379 | +203.4% | 0.01% | +160.0% |
| Q4 2020 | $237,000 | – | 4,739 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SIGULER GUFF ADVISERS, LLC | 6,761,970 | $263,446,000 | 59.92% |
| Memorial Sloan Kettering Cancer Center | 1,128,255 | $43,957,000 | 50.90% |
| Vantage Consulting Group Inc | 2,727,854 | $106,277,000 | 41.47% |
| Indie Asset Partners, LLC | 756,874 | $29,488,000 | 22.15% |
| Overbrook Management Corp | 723,250 | $28,178,000 | 6.25% |
| Brown University | 621,759 | $24,224,000 | 5.93% |
| Geo Capital Gestora de Recursos Ltd | 200,692 | $8,527,000 | 3.82% |
| Lagoda Investment Management, L.P. | 141,560 | $5,515,000 | 2.97% |
| Greytown Advisors Inc. | 131,143 | $5,109,000 | 2.47% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 2,025,610 | $78,918,000 | 2.41% |